1529-0131/asset/cover.gif?v=1&s=104d5c2bb8ef72deba26790b855af7ab80697a0e "Arthritis & Rheumatism")
Direct Link:
1529-0131/asset/olbannerleft.gif?v=1&s=897b81612b4ad6cae003112184adc709261d5f61)
1529-0131/asset/olbannerright.gif?v=1&s=04654f5ea3cbb01656383e0c0d04b16fd0a9a896)
Research Article
You have full text access to this OnlineOpen article
Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial
Article first published online: 8 NOV 2002
DOI: 10.1002/art.10578
Copyright © 2002 by the American College of Rheumatology
Additional Information
How to Cite
Nuki, G., Bresnihan, B., Bear, M. B. and McCabe, D. (2002), Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism, 46: 2838–2846. doi: 10.1002/art.10578
Publication History
- Issue published online: 8 NOV 2002
- Article first published online: 8 NOV 2002
- Manuscript Accepted: 3 JUL 2002
- Manuscript Received: 27 DEC 2001
Funded by
- Amgen, Inc.
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , , , , , , , , , Distinct roles of trauma and transfusion in induction of immune modulation after injury, Transfusion, 2012, 52, 5
- 2, , , , , Chronic blockade of interleukin-1 (IL-1) prevents and attenuates neuropathic pain behavior and spontaneous ectopic neuronal activity following nerve injury, European Journal of Pain, 2011, 15, 3Direct Link:
- 3, , Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes, Nature Reviews Drug Discovery, 2011, 10, 6, 439
- 4, , , , , , , Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations, Rheumatology International, 2011, 32, 2, 295
- 5, , , , , Interleukin-23 as a potential therapeutic target for rheumatoid arthritis, Molecular and Cellular Biochemistry, 2011, 361, 1-2, 243
- 6, , , , , , , , , , Regulatory immune responses induced by IL-1 receptor antagonist in rheumatoid arthritis, Molecular Immunology, 2011, 49, 1-2, 290
- 7, , Safety of biologic therapy in rheumatoid arthritis, Nature Reviews Rheumatology, 2011, 7, 11, 639
- 8, , The NLRP3 inflammasome in health and disease: the good, the bad and the ugly, Clinical & Experimental Immunology, 2011, 166, 1Direct Link:
- 9, , , Blockade of interleukin 1 in type 1 diabetes mellitus, Nature Reviews Endocrinology, 2010, 6, 3, 158
- 10, , , , , , , , , , , , Gene profiling predicts rheumatoid arthritis responsiveness to IL-1Ra (anakinra), Rheumatology, 2010, 50, 2, 283
- 11, Immunotherapy of Rheumatoid Arthritis Targeting Inflammatory Cytokines and Autoreactive T Cells, Archivum Immunologiae et Therapiae Experimentalis, 2010, 58, 1, 27
- 12, , , , , , , , , , , , Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study, Journal of Cerebral Blood Flow & Metabolism, 2010, 31, 2, 439
- 13, , Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis, Nature Reviews Rheumatology, 2009, 5, 10, 578
- 14, , , Pathogenic bone loss in rheumatoid arthritis: mechanisms and therapeutic approaches, International Journal of Clinical Rheumatology, 2009, 4, 5, 561
- 15, , , , , Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra, British Journal of Dermatology, 2009, 161, 5Direct Link:
- 16, , The anti-interleukin-1 in type 1 diabetes action trial—background and rationale, Diabetes/Metabolism Research and Reviews, 2009, 25, 4Direct Link:
- 17, , , , , The glucosamine-mediated induction of CHOP reduces the expression of inflammatory cytokines by modulating JNK and NF-κB in LPS-stimulated RAW264.7 cells, Genes & Genomics, 2009, 31, 3, 251
- 18
- 19, , , , , , , , , , , , Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study, Clinical Rheumatology, 2008, 28, 2, 129
- 20, , , , , , , , , , , , Comparison of anti-rheumatic effects of local RNAi-based therapy in collagen induced arthritis rats using various cytokine genes as molecular targets, Modern Rheumatology, 2008, 19, 2, 125
- 21, , Cytokines and anti-cytokines as therapeutics — An update, European Journal of Pharmacology, 2008, 579, 1-3, 1
- 22, , , , , , , , Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer, Cytokine, 2008, 42, 1, 77
- 23, , , , , , , , , , , , Development of Interleukin-1 Receptor Antagonist Mutants with Enhanced Antagonistic ActivityIn Vitroand Improved Therapeutic Efficacy in Collagen-Induced Arthritis, Journal of Immunotoxicology, 2008, 5, 2, 189
- 24, , , , Interleukin-1 receptor antagonist restores homeostatic function and limits multiorgan damage in heatstroke, European Journal of Applied Physiology, 2008, 103, 5, 561
- 25, , MAPK phosphatases as novel targets for rheumatoid arthritis, Expert Opinion on Therapeutic Targets, 2008, 12, 7, 795
- 26, , , , , , , , Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage, British Journal of Clinical Pharmacology, 2008, 65, 3Direct Link:
- 27, , , , , , , , T cell dependence of chronic destructive murine arthritis induced by repeated local activation of toll-like receptor–driven pathways: Crucial role of both interleukin-1β and interleukin-17, Arthritis & Rheumatism, 2008, 58, 1Direct Link:
- 28, , A biológiai terápia lehetőségei az arthritisek és a szisztémás autoimmun betegségek kezelésében, Orvosi Hetilap, 2007, 148, 0, 63
- 29, , CD3-specific antibodies: a portal to the treatment of autoimmunity, Nature Reviews Immunology, 2007, 7, 8, 622
- 30, , , , , , , , Development and characterization of a fusion protein between thermally responsive elastin-like polypeptide and interleukin-1 receptor antagonist: Sustained release of a local antiinflammatory therapeutic, Arthritis & Rheumatism, 2007, 56, 11Direct Link:
- 31, , , , , , , , , Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations, Journal of Cerebral Blood Flow & Metabolism, 2007, 28, 2, 387
- 32, , , , , Molecular basis of MAPK-activated protein kinase 2:p38 assembly, Proceedings of the National Academy of Sciences, 2007, 104, 15, 6353
- 33, , , , , Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of ‘off’ episodes in patients with Parkinson's disease, Current Medical Research and Opinion, 2007, 23, 4, 741
- 34, , , Tratamiento de la artritis reumatoide con anakinra: revisión sistemática, ReumatologÃa ClÃnica, 2007, 3, 4, 153
- 35, , , Treatment of Rheumatoid Arthritis With Anakinra: A Systematic Review, ReumatologÃa ClÃnica (English Edition), 2007, 3, 4, 153
- 36
- 37, Anakinra (Interleukin-1 Receptor Antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis, Advances in Therapy, 2006, 23, 2, 208
- 38, Anakinra in the treatment of rheumatic disease, Expert Review of Clinical Immunology, 2006, 2, 3, 331
- 39, , , , Aspectos actuales y perspectivas de futuro del tratamiento de la artritis reumatoide, Medicine - Programa de Formación Médica Continuada Acreditado, 2006, 9, 69, 4436
- 40, Emerging Therapies in Juvenile Rheumatoid/Idiopathic Arthritis, Current Problems in Pediatric and Adolescent Health Care, 2006, 36, 3, 97
- 41GuÃas y recomendaciones del Colegio Mexicano de ReumatologÃa para el uso de agentes biológicos en enfermos reumáticos, ReumatologÃa ClÃnica, 2006, 2, 2, 78
- 42, , , , , InforMatrix®: treatment of rheumatoid arthritis using biologicals, Expert Opinion on Pharmacotherapy, 2006, 7, 13, 1769
- 43, , , , Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis, Arthritis Care & Research, 2006, 55, 6Direct Link:
- 44, , , Mechanisms underlying joint pain, Drug Discovery Today: Disease Mechanisms, 2006, 3, 3, 357
- 45, , , , , , , , p21Cip1 Is Required for the Development of Monocytes and Their Response to Serum Transfer-induced Arthritis, The American Journal of Pathology, 2006, 168, 5, 1531
- 46, Therapeutic strategies targeting interleukin-1 in vascular inflammation, Drug Discovery Today: Therapeutic Strategies, 2006, 3, 3, 367
- 47
- 48, , , , , , Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients, British Journal of Dermatology, 2005, 153, 2Direct Link:
- 49, , , , , , Anti-inflammatory effects of UV-irradiated lymphocytes: induction of IL-1Ra upon phagocytosis by monocyte/macrophages, Clinical Immunology, 2005, 114, 3, 320
- 50, , New therapies for rheumatoid arthritis, Clinical & Experimental Immunology, 2005, 140, 2Direct Link:
- 51
- 52, , , , On-Column Refolding and Purification of Recombinant Human Interleukin-1 Receptor Antagonist (rHuIL-1ra) Expressed as Inclusion Body in Escherichia coli, Biotechnology Letters, 2005, 27, 16, 1177
- 53, , , , Rheumatic diseases: the effects of inflammation on bone, Immunological Reviews, 2005, 208, 1Direct Link:
- 54
- 55, , , Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis, Expert Opinion on Biological Therapy, 2004, 4, 8, 1333
- 56, Anakinra: Review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis, Clinical Therapeutics, 2004, 26, 12, 1960
- 57
- 58, Biological Mediators of Acute Inflammation, AACN Clinical Issues: Advanced Practice in Acute and Critical Care, 2004, 15, 1, 3
- 59, , Bone loss in inflammatory arthritis: mechanisms and treatment strategies, Current Opinion in Rheumatology, 2004, 16, 4, 419
- 60, Durability and Rapidity of Response to Anakinra in Patients with Rheumatoid Arthritis, Drugs, 2004, 64, 22, 2493
- 61, , , , , , IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system, Biochemical and Biophysical Research Communications, 2004, 314, 2, 363
- 62, Measurement of structural abnormalities in arthritis using radiographic images, Radiologic Clinics of North America, 2004, 42, 1, 109
- 63, , , New Drugs for Rheumatoid Arthritis, New England Journal of Medicine, 2004, 350, 21, 2167
- 64, , , , Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra, Arthritis & Rheumatism, 2004, 50, 2Direct Link:
- 65, The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis, Rheumatic Disease Clinics of North America, 2004, 30, 2, 365
- 66, , , , The use of methotrexate in rheumatoid arthritis, Seminars in Arthritis and Rheumatism, 2004, 34, 1, 465
- 67, , Therapeutic advances in rheumatoid arthritis, APLAR Journal of Rheumatology, 2004, 7, 1Direct Link:
- 68Current Awareness: Pharmacoepidemiology and Drug Safety, Pharmacoepidemiology and Drug Safety, 2003, 12, 4Direct Link:
- 69, Disease-modifying antirheumatic drug therapy for spondyloarthropathies, Current Opinion in Rheumatology, 2003, 15, 3, 205
- 70, , , , , , , , , , Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis, Arthritis & Rheumatism, 2003, 48, 10Direct Link:
- 71, , Novel therapies in pediatric rheumatic diseases, Current Opinion in Pediatrics, 2003, 15, 6, 579
- 72, , Pharmacological treatment of established rheumatoid arthritis, Best Practice & Research Clinical Rheumatology, 2003, 17, 5, 811
- 73, Potential new drugs for therapy of chronic obstructive pulmonary disease, Expert Opinion on Investigational Drugs, 2003, 12, 7, 1067
- 74, Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis, Expert Opinion on Drug Safety, 2003, 2, 4, 347
- 75, , , Secondary immune deficiencies associated with biological therapeutics, Current Allergy and Asthma Reports, 2003, 3, 5, 389
- 76, The therapeutic potential of TNF-α blockade in rheumatoid arthritis, Expert Opinion on Investigational Drugs, 2003, 12, 7, 1087
- 77, , Use of immunosuppressive agents in uveitis, Current Opinion in Ophthalmology, 2003, 14, 6, 399
- 78, , , , , , , , , , , , , , , , , , , , , Adverse effects of biologics: a network meta-analysis and Cochrane overview, The Cochrane Library,Direct Link:
- 79, , Anakinra for rheumatoid arthritis, The Cochrane Library,Direct Link:
- 80, , , , , Interleukin-1 receptor antagonist for treating periodontitis, The Cochrane Library,Direct Link: